Future directions for pharmacotherapies for treatment-resistant bipolar disorder

Current Neuropharmacology

Volumn 13, Issue 5, 2015, Pages 656-662

  Dodd, Seetal ^a,b,c   Fernandes, Brisa S ^a,c,d   Dean, Olivia M ^a,b,c  

^a DEAKIN UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c BARWON HEALTH   (Australia)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Bipolar disorder; Inflammation; Nitrosative stress; Oxidative stress; Pathways; Pharmacotherapy; Receptors; Treatment targets

Indexed keywords

ANKYRIN; BETA CATENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; CELECOXIB; CIMICOXIB; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; KETAMINE; MELATONIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROKININ 1 RECEPTOR; PROTEIN BCL 2; PURINERGIC RECEPTOR AFFECTING AGENT; ROFECOXIB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; NEUROPEPTIDE;

APOPTOSIS; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); COMORBIDITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC POLYMORPHISM; HUMAN; NITROSATIVE STRESS; OXIDATIVE STRESS; PROTEIN EXPRESSION; PSYCHOPHARMACOTHERAPY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESISTANT BIPOLAR DISORDER; TREATMENT RESISTANT DEPRESSION; UPREGULATION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; CHOLINERGIC AGENTS; DRUG DISCOVERY; HUMANS; NEUROPEPTIDES; PURINERGIC AGENTS; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84946710182     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X13666150630175841     Document Type: Article

References (73)

1. The Wellcome Trust Case Control Consortium, Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, 447(7145), 661-678. http://dx.doi.org/10.1038/nature05911
2. Andreazza, A.C.; Young, L.T. The neurobiology of bipolar disorder: identifying targets for specific agents and synergies for combination treatment. Int. J. Neuropsychopharmacol., 2014, 17(7), 1039-1052. http://dx.doi.org/10.1017/S1461145713000096
3. Bowden, C.L.; Calabrese, J.R.; McElroy, S.L.; Gyulai, L.; Wassef, A.; Petty, F.; Pope, H.G., Jr.; Chou, J.C.; Keck, P.E., Jr.; Rhodes, L.J.; Swann, A.C.; Hirschfeld, R.M.; Wozniak, P.J. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch. Gen. Psychiatry, 2000, 57(5), 481-489. http://dx.doi.org/10.1001/archpsyc.57.5.481
4. Wadee, A.A.; Kuschke, R.H.; Wood, L.A.; Berk, M.; Ichim, L.; Maes, M. Serological observations in patients suffering from acute manic episodes. Hum. Psychopharmacol., 2002, 17(4), 175-179. http://dx.doi.org/10.1002/hup.390
5. Moylan, S.; Berk, M.; Dean, O.M.; Samuni, Y.; Williams, L.J.; O'Neil, A.; Hayley, A.C.; Pasco, J.A.; Anderson, G.; Jacka, F.N.; Maes, M. Oxidative and nitrosative stress in depression: Why so much stress? Neurosci. Biobehav. Rev., 2014, 45C, 46-62. http://dx.doi.org/10.1016/j.neubiorev.2014.05.007
6. Schmaal, L.; Berk, L.; Hulstijn, K.P.; Cousijn, J.; Wiers, R.W.; van den Brink, W. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur. Addict. Res., 2011, 17(4), 211-216. http://dx.doi.org/10.1159/000327682
7. Loebel, A.; Cucchiaro, J.; Silva, R.; Kroger, H.; Hsu, J.; Sarma, K.; Sachs, G. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry, 2014, 171(2), 160-168. http://dx.doi.org/10.1176/appi.ajp.2013.13070984
8. Loebel, A.; Cucchiaro, J.; Silva, R.; Kroger, H.; Sarma, K.; Xu, J.; Calabrese, J.R. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am. J. Psychiatry, 2014, 171(2), 169-177. http://dx.doi.org/10.1176/appi.ajp.2013.13070985
9. Berk, M.; Dodd, S. Efficacy of atypical antipsychotics in bipolar disorder. Drugs, 2005, 65(2), 257-269. http://dx.doi.org/10.2165/00003495-200565020-00006
10. Mallinger, A.G.; Thase, M.E.; Haskett, R.; Buttenfield, J.; Luckenbaugh, D.A.; Frank, E.; Kupfer, D.J.; Manji, H.K. Verapamil augmentation of lithium treatment improves outcome in mania unresponsive to lithium alone: preliminary findings and a discussion of therapeutic mechanisms. Bipolar Disord., 2008, 10(8), 856-866. http://dx.doi.org/10.1111/j.1399-5618.2008.00636.x
11. Kulkarni, J.; Filia, S.; Berk, L.; Filia, K.; Dodd, S.; de Castella, A.; Brnabic, A.J.; Lowry, A.J.; Kelin, K.; Montgomery, W.; Fitzgerald, P.B.; Berk, M. Treatment and outcomes of an Australian cohort of outpatients with bipolar I or schizoaffective disorder over twentyfour months: implications for clinical practice. BMC Psychiatry, 2012, 12, 228. http://dx.doi.org/10.1186/1471-244X-12-228
12. Fountoulakis, K.N.; Kelsoe, J.R.; Akiskal, H. Receptor targets for antidepressant therapy in bipolar disorder: an overview. J. Affect. Disord., 2012, 138(3), 222-238. http://dx.doi.org/10.1016/j.jad. 2011.04.043
13. Malhi, G.S.; Adams, D.; Cahill, C.M.; Dodd, S.; Berk, M. The management of individuals with bipolar disorder: a review of the evidence and its integration into clinical practice. Drugs, 2009, 69(15), 2063-2101.
14. Berk, M.; Dodd, S.; Kauer-Sant'anna, M.; Malhi, G.S.; Bourin, M.; Kapczinski, F.; Norman, T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. Suppl., 2007, (434), 41-49. http://dx.doi.org/10.1111/j.1600-0447.2007.01058.x
15. Mah, L.; Zarate, C.A., Jr.; Nugent, A.C.; Singh, J.B.; Manji, H.K.; Drevets, W.C., Neural mechanisms of antidepressant efficacy of the dopamine receptor agonist pramipexole in treatment of bipolar depression. Int. J. Neuropsychopharmacol., 2011, 14(4), 545-551. http://dx.doi.org/10.1017/S1461145710001203
16. Veselinovic, T.; Paulzen, M.; Grunder, G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev. Neurother., 2013, 13(11), 1141-1159. http://dx.doi.org/10.1586/14737175.2013.853448
17. Calabrese, J.R.; Frye, M.A.; Yang, R.; Ketter, T.A. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial. J. Clin. Psychiatry, 2014. http://dx.doi.org/10.4088/JCP.13m08951
18. Calabrese, J.R.; Ketter, T.A.; Youakim, J.M.; Tiller, J.M.; Yang, R.; Frye, M.A. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study. J. Clin. Psychiatry, 2010, 71(10), 1363-1370. http://dx.doi.org/10.4088/JCP.09m05900gry
19. Frye, M.A.; Grunze, H.; Suppes, T.; McElroy, S.L.; Keck, P.E., Jr.; Walden, J.; Leverich, G.S.; Altshuler, L.L.; Nakelsky, S.; Hwang, S.; Mintz, J.; Post, R.M. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am. J. Psychiatry, 2007, 164(8), 1242-1249. http://dx.doi.org/10.1176/appi.ajp.2007.06060981
20. Woo, T.U.; Walsh, J.P.; Benes, F.M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry, 2004, 61(7), 649-657. http://dx.doi.org/10.1001/archpsyc.61.7.649
21. Martucci, L.; Wong, A.H.; De Luca, V.; Likhodi, O.; Wong, G.W.; King, N.; Kennedy, J.L. N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr. Res., 2006, 84(2 3), 214-221. http://dx.doi.org/10.1016/j.schres.2006.02.001
22. Mundo, E.; Tharmalingham, S.; Neves-Pereira, M.; Dalton, E.J.; Macciardi, F.; Parikh, S.V.; Bolonna, A.; Kerwin, R.W.; Arranz, M.J.; Makoff, A.J.; Kennedy, J.L. Evidence that the N-methyl-Daspartate subunit 1 receptor gene (GRIN1) confers susceptibility to bipolar disorder. Mol. Psychiatry, 2003, 8(2), 241-245. http://dx.doi.org/10.1038/sj.mp.4001218
23. Zarate, C.A., Jr.; Brutsche, N.E.; Ibrahim, L.; Franco-Chaves, J.; Diazgranados, N.; Cravchik, A.; Selter, J.; Marquardt, C.A.; Liberty, V.; Luckenbaugh, D.A. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry, 2012, 71(11), 939-946. http://dx.doi.org/10.1016/j.biopsych.2011.12.010
24. Niciu, M.J.; Luckenbaugh, D.A.; Ionescu, D.F.; Guevara, S.; Machado-Vieira, R.; Richards, E.M.; Brutsche, N.E.; Nolan, N.M.; Zarate, C.A., Jr., Clinical predictors of ketamine response in treatment-resistant major depression. J. Clin. Psychiatry, 2014, 75(5), e417-423. http://dx.doi.org/10.4088/JCP.13m08698
25. Lee, B.H.; Hwang, D.M.; Palaniyar, N.; Grinstein, S.; Philpott, D.J.; Hu, J. Activation of P2X(7) receptor by ATP plays an important role in regulating inflammatory responses during acute viral infection. PLoS One, 2012, 7(4), e35812. http://dx.doi.org/10.1371/journal.pone.0035812
26. Lucae, S.; Salyakina, D.; Barden, N.; Harvey, M.; Gagne, B.; Labbe, M.; Binder, E.B.; Uhr, M.; Paez-Pereda, M.; Sillaber, I.; Ising, M.; Bruckl, T.; Lieb, R.; Holsboer, F.; Muller-Myhsok, B. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum. Mol. Genet., 2006, 15(16), 2438-2445. http://dx.doi.org/10.1093/hmg/ddl166
27. Backlund, L.; Nikamo, P.; Hukic, D.S.; Ek, I.R.; Traskman-Bendz, L.; Landen, M.; Edman, G.; Schalling, M.; Frisen, L.; Osby, U. Cognitive manic symptoms associated with the P2RX7 gene in bipolar disorder. Bipolar Disord., 2011, 13(5 6), 500-508. http://dx.doi.org/10.1111/j.1399-5618.2011.00952.x
28. Akhondzadeh, S.; Milajerdi, M.R.; Amini, H.; Tehrani-Doost, M. Allopurinol as an adjunct to lithium and haloperidol for treatment of patients with acute mania: a double-blind, randomized, placebocontrolled trial. Bipolar Disord., 2006, 8(5 Pt 1), 485-489. http://dx.doi.org/10.1111/j.1399-5618.2006.00363.x
29. Machado-Vieira, R.; Soares, J.C.; Lara, D.R.; Luckenbaugh, D.A.; Busnello, J.V.; Marca, G.; Cunha, A.; Souza, D.O.; Zarate, C.A. Jr.; Kapczinski, F., A double-blind, randomized, placebo-controlled 4-week study on the efficacy and safety of the purinergic agents allopurinol and dipyridamole adjunctive to lithium in acute bipolar mania. J. Clin. Psychiatry, 2008, 69(8), 1237-1245. http://dx.doi.org/10.4088/JCP.v69n0806
30. Davis, K.L.; Berger, P.A.; Hollister, L.E.; Defraites, E. Physostigmine in mania. Arch. Gen. Psychiatry, 1978, 35(1), 119-122. http://dx.doi.org/10.1001/archpsyc.1978.01770250121012
31. Furey, M.L.; Drevets, W.C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebocontrolled clinical trial. Arch. Gen. Psychiatry, 2006, 63(10), 1121-1129. http://dx.doi.org/10.1001/archpsyc.63.10.1121
32. Yehuda, R.; Brand, S.; Yang, R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry, 2006, 59(7), 660-663. http://dx.doi.org/10.1016/j.biopsych.2005.08.027
33. Thiele, T.E.; Koh, M.T.; Pedrazzini, T. Voluntary alcohol consumption is controlled via the neuropeptide Y Y1 receptor. J. Neurosci., 2002, 22(3), RC208.
34. Nikisch, G.; Baumann, P.; Liu, T.; Mathe, A.A. Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Int. J. Neuropsychopharmacol., 2012, 15(8), 1051-1061. http://dx.doi.org/10.1017/S1461145711001556
35. Machado-Vieira, R.; Zarate, C.A., Jr. Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments. Depress Anxiety, 2011, 28(4), 267-281. http://dx.doi.org/10.1002/da.20800
36. Gonzalez-Castro, T.B.; Nicolini, H.; Lanzagorta, N.; Lopez- Narvaez, L.; Genis, A.; Pool, G. S.; Tovilla-Zarate, C.A. The role of brain-derived neurotrophic factor (BDNF) Val66Met genetic polymorphism in bipolar disorder: a case-control study, comorbidities, and meta-analysis of 16,786 subjects. Bipolar Disord., 2014, 17, 27-38. http://dx.doi.org/10.1111/bdi.12227
37. Cullen, S.P.; Martin, S.J. Caspase activation pathways: some recent progress. Cell Death Differ., 2009, 16(7), 935-938. http://dx.doi.org/10.1038/cdd.2009.59
38. O'Brien, T.; Linton, S.D. Design of Caspase Inhibitors as Potential Clinical Agents. CRC Press, Taylor and Francis Group: Boca Raton, FL, 2009.
39. Han, B.H.; Xu, D.; Choi, J.; Han, Y.; Xanthoudakis, S.; Roy, S.; Tam, J.; Vaillancourt, J.; Colucci, J.; Siman, R.; Giroux, A.; Robertson, G.S.; Zamboni, R.; Nicholson, D.W.; Holtzman, D.M. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxicischemic brain injury. J. Biol. Chem., 2002, 277(33), 30128-30136. http://dx.doi.org/10.1074/jbc.M202931200
40. Dean, O.M.; Data-Franco, J.; Giorlando, F.; Berk, M., Minocycline: therapeutic potential in psychiatry. CNS Drugs, 2012, 26(5), 391-401. http://dx.doi.org/10.2165/11632000-000000000-00000
41. Dodd, S.; Dean, O.; Copolov, D.L.; Malhi, G.S.; Berk, M. Nacetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther., 2008, 8(12), 1955-1962. http://dx.doi.org/10.1517/14728220802517901
42. Kulkarni, J. Oestrogen--a new treatment approach for schizophrenia? Med. J. Aust., 2009, 190(4 Suppl), S37-38.
43. He, J.; Kong, J.; Tan, Q.R.; Li, X.M. Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models. Cell Adh. Migr., 2009, 3(1), 129-137. http://dx.doi.org/10.4161/cam.3.1.7401
44. Poo, M.M. Neurotrophins as synaptic modulators. Nat. Rev. Neurosci., 2001, 2(1), 24-32. http://dx.doi.org/10.1038/35049004
45. Cohen-Cory, S.; Kidane, A.H.; Shirkey, N.J.; Marshak, S. Brainderived neurotrophic factor and the development of structural neuronal connectivity. Dev. Neurobiol., 2010, 70(5), 271-288. http://dx.doi.org/10.1002/dneu.20774
46. Frey, B.N.; Andreazza, A.C.; Houenou, J.; Jamain, S.; Goldstein, B.I.; Frye, M.A.; Leboyer, M.; Berk, M.; Malhi, G.S.; Lopez- Jaramillo, C.; Taylor, V.H.; Dodd, S.; Frangou, S.; Hall, G.B.; Fernandes, B.S.; Kauer-Sant'Anna, M.; Yatham, L.N.; Kapczinski, F.; Young, L.T. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust. N. Z. J. Psychiatry, 2013, 47(4), 321-332. http://dx.doi.org/10.1177/0004867413478217
47. Friedrich, M.J. Research on psychiatric disorders targets inflammation. JAMA, 2014, 312(5), 474-476. http://dx.doi.org/10.1001/jama.2014.8276
48. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry, 2013, 70(1), 31-41. http://dx.doi.org/10.1001/2013.jamapsychiatry.4
49. Kauer-Sant'Anna, M.; Andreazza, A.C.; Valvassori, S.S.; Martins, M.R.; Barbosa, L.M.; Schwartsmann, G.; Roesler, R.; Quevedo, J.; Kapczinski, F. A gastrin-releasing peptide receptor antagonist blocks D-amphetamine-induced hyperlocomotion and increases hippocampal NGF and BDNF levels in rats. Peptides, 2007, 28(7), 1447-1452. http://dx.doi.org/10.1016/j.peptides.2007.06.010
50. Leonard, B.; Maes, M. Mechanistic explanations how cellmediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev., 2012, 36(2), 764-785. http://dx.doi.org/10.1016/j. neubiorev.2011.12.005
51. Dhabhar, F.S. Enhancing versus Suppressive Effects of Stress on Immune Function: Implications for Immunoprotection versus Immunopathology. Allergy Asthma Clin. Immunol., 2008, 4(1), 2-11. http://dx.doi.org/10.1186/1710-1492-4-1-2
52. Asnis, G.M.; De La Garza, R. 2nd, Interferon-induced depression: strategies in treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2005, 29(5), 808-818. http://dx.doi.org/10.1016/j.pnpbp.2005.03.006
53. Post, R.M.; Altshuler, L.; Leverich, G.; Nolen, W.; Kupka, R.; Grunze, H.; Frye, M.; Suppes, T.; McElroy, S.; Keck, P.; Rowe, M. More stressors prior to and during the course of bipolar illness in patients from the United States compared with the Netherlands and Germany. Psychiatry Res., 2013, 210,880-6. http://dx.doi.org/10.1016/j.psychres.2013.08.007
54. Lumeng, C.N. Innate immune activation in obesity. Mol. Aspects Med., 2013, 34(1), 12-29. http://dx.doi.org/10.1016/j.mam.2012.10.002
55. McNamara, R.K.; Lotrich, F.E. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target? Expert Rev. Neurother., 2012, 12(9), 1143-1161. http://dx.doi.org/10.1586/ern.12.98
56. Torrey, E.F.; Davis, J.M. Adjunct treatments for schizophrenia and bipolar disorder: what to try when you are out of ideas. Clin. Schizophr. Relat. Psychoses, 2012, 5(4), 208-216. http://dx.doi.org/10.3371/CSRP.5.4.5
57. Schonbeck, U.; Libby, P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation, 2004, 109(21 Suppl 1), II18-26.
58. Stafford, L.; Berk, M. The use of statins after a cardiac intervention is associated with reduced risk of subsequent depression: proof of concept for the inflammatory and oxidative hypotheses of depression? J. Clin. Psychiatry, 2011, 72(9), 1229-1235.
59. Grenham, S.; Clarke, G.; Cryan, J.F.; Dinan, T.G. Brain-gutmicrobe communication in health and disease. Front. Physiol., 2011, 2, 94. http://dx.doi.org/10.3389/fphys.2011.00094
60. Berk, M.; Copolov, D.L.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Bush, A.I. N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol. Psychiatry, 2008, 64(6), 468-475. http://dx.doi.org/10.1016/j.biopsych.2008.04.022
61. Andreazza, A.C.; Shao, L.; Wang, J.F.; Young, L.T. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch. Gen. Psychiatry, 2010, 67(4), 360-368. http://dx.doi.org/10.1001/archgenpsychiatry.2010.22
62. Fattal, O.; Link, J.; Quinn, K.; Cohen, B.H.; Franco, K., Psychiatric comorbidity in 36 adults with mitochondrial cytopathies. CNS Spectr., 2007, 12(6), 429-438.
63. Prince, J.A.; Yassin, M.S.; Oreland, L. Neuroleptic-induced mitochondrial enzyme alterations in the rat brain. J. Pharmacol. Exp. Ther., 1997, 280(1), 261-267.
64. Hroudova, J.; Fisar, Z., Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro. Endocrinol., Lett., 2010, 31(3), 336-342.
65. Pfeffer, G.; Chinnery, P.F. Diagnosis and treatment of mitochondrial myopathies. Ann. Med., 2013, 45(1), 4-16. http://dx.doi.org/10.3109/07853890.2011.605389
66. Anderson, G.; Maes, M., Local melatonin regulates inflammation resolution: a common factor in neurodegenerative, psychiatric and systemic inflammatory disorders. CNS Neurol. Disord. Drug Targets, 2014, 13(5), 817-827. http://dx.doi.org/10.2174/1871527313666140711091400
67. Soreca, I., Circadian rhythms and sleep in bipolar disorder: implications for pathophysiology and treatment. Curr. Opin. Psychiatry, 2014, 27(6), 467-471. http://dx.doi.org/10.1097/YCO.0000000000000108
68. Martin, M.; Macias, M.; Leon, J.; Escames, G.; Khaldy, H.; Acuna- Castroviejo, D. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int. J. Biochem. Cell Biol., 2002, 34(4), 348-357. http://dx.doi.org/10.1016/S1357-2725(01)00138-8
69. Romo-Nava, F.; Alvarez-Icaza, G. D.; Fresan-Orellana, A.; Saracco, A. R.; Becerra-Palars, C.; Moreno, J.; Ontiveros, U. M.P.; Berlanga, C.; Heinze, G.; Buijs, R.M. Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, doubleblind, parallel-group, placebo-controlled clinical trial. Bipolar Disord., 2014, 16(4), 410-421. http://dx.doi.org/10.1111/bdi.12196
70. Tosini, G.; Ye, K.; Iuvone, P.M. N-acetylserotonin: neuroprotection, neurogenesis, and the sleepy brain. Neuroscientist, 2012, 18(6), 645-653. http://dx.doi.org/10.1177/1073858412446634
71. Clarke, G.; O'Mahony, S.M.; Dinan, T.G.; Cryan, J.F. Priming for health: gut microbiota acquired in early life regulates physiology, brain and behaviour. Acta Paediatr., 2014, 103(8), 812-819. http://dx.doi.org/10.1111/apa.12674
72. Bested, A.C.; Logan, A.C.; Selhub, E.M. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III - convergence toward clinical trials. Gut. Pathog., 2014, 5(1), 4. http://dx.doi.org/10.1186/1757-4749-5-4
73. Bested, A.C.; Logan, A.C.; Selhub, E.M. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: Part II - contemporary contextual research. Gut. Pathog., 2013, 5(1), 3. http://dx.doi.org/10.1186/1757-4749-5-3